Network Pharmacology-based Strategy for Studying the Mechanism of Gegen Qinlian Decoction for the Treatment of Acute Colitis

Wang, Tingting; Xu, Yanwen; Ji, Wanli; An, Rui

doi:10.21203/rs.3.rs-46831/v1

Cited by 1 publication

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Zhang Jiacheng, it was found that the minimum amount of water added for GQD decoction was nine times the amount of the drug mass, and the time of decoction was 50 min; otherwise, it affected the precipitation of the active ingredients of the drug, thus affecting the efficacy (20). Its key constituent flavonoids, alkaloids, and saponins were identified through ultra-high-performance liquid chromatography and mass spectrometry (21). It has the effect of clearing the liver, diarrhea, heat, and intestines, and can be applied to diseases such as acute gastroenteritis, ulcerative colitis, gastroparesis, colon cancer, diabetes mellitus with lower limb vasculopathy, and peripheral neuropathy (22)(23)(24)(25)(26).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of Gegen Qinlian decoction in the treatment of type II diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials

Tan,

Liu,

Huang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

AimThe study aims to systematically assess the efficacy and safety of Gegen Qinlian decoction in the treatment of type 2 diabetes mellitus.MethodsWe systematically searched a total of nine databases from the time of creation to 20 March 2023. The quality of the literature was assessed using the risk of bias assessment tool in the Cochrane Handbook. RevMan 5. 3 and Stata 14.0 were applied to conduct meta-analysis.ResultsA total of 17 studies, encompassing 1,476 patients, were included in the study. Gegen Qinlian decoction combined with conventional treatment was found to significantly reduce FBG (MD = −0.69 mmol/L, 95% CI −0.84 to −0.55, p < 0.01; I2 = 67%, p<0.01), 2hPG (MD = −0.97 mmol/L, 95% CI −1.13 to −0.81, p < 0.01; I2 = 37%, p=0.09), HbA1c (MD = −0.65%, 95% CI −0.78 to −0.53, p < 0.01; I2 = 71%, p<0.01), TC (MD = −0.51 mmol/L, 95% CI −0.62 to −0.41, p < 0.01; I2 = 45%, p=0.09), TG (MD = −0.17mmol/L, 95% CI −0.29 to −0.05, p < 0.01; I2 = 78%, p<0.01), LDL-C (MD = −0.38mmol/L, 95% CI −0.53 to −0.23, p < 0.01; I2 = 87%, p<0.01), HOMA-IR (SMD = −1.43, 95% CI −2.32 to −0.54, p < 0.01; I2 = 94%, p<0.01), and improved HDL-C (MD = 0.13 mmol/L, 95% CI 0.09–0.17, p < 0.01; I2 = 30%, p=0.24). Only three studies explored the differences in efficacy between GQD alone and conventional treatment in improving glucose–lipid metabolism and insulin resistance, and some of the outcome indicators, such as 2hPG and HDL-C, were examined in only one study. Therefore, the effect of GQD alone on glucose–lipid metabolism and insulin resistance cannot be fully determined, and more high-quality studies are needed to verify it. Publication bias analysis revealed no bias in the included studies.ConclusionGegen Qinlian Decoction has certain efficacy and safety in enhancing glycolipid metabolism and alleviating insulin resistance, potentially serving as a complementary therapy for type 2 diabetes mellitus. Rigorous, large-sample, multicenter RCTs are needed to verify this.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023413758, PROSPERO CRD42023413758.

show abstract

Section: Introductionmentioning

confidence: 99%